Clinical Trial Update: Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients [Phase 2]

View source ↗

Summary

A Phase 2a clinical trial update for DW-3101 in patients with acute or chronic gastritis, focusing on optimum dosage and stability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastritis

Drugs mentioned

• DW-3101

Snippet

Sponsor: Daewon Pharmaceutical Co., Ltd. | Conditions: Acute and Chronic Gastric Inflammation Patients | Phase 2 | Status: UNKNOWN